Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
OGI · Nasdaq · United States · Pharmaceutical Preparations
In shortORGANIGRAM GLOBAL INC. is loss-making, burns cash and carries moderate debt, with revenue growing (+9.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -22.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -28.4% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -11.2% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -11.7% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 4.92× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.00× | 100/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | 1.26 | 4/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -0.5% | 18/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 0 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 5 | 67/100 |
| Revenue growth volatility | 237.0% | 0/100 |
| Operating margin volatility | 73.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 22.6% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2024 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
1 older year available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
CAD millions; negative values in parentheses.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY24 |
|---|---|---|---|---|---|
| Revenue | 80 | 87 | 79 | 146 | 160 |
| Cost of revenue | 43 | 105 | 104 | 119 | 111 |
| Gross profit | 48 | (56) | (28) | 32 | 48 |
| Research & development | 0.4 | 1.3 | 3.6 | 6 | 11 |
| Selling, general & admin | 19 | 28 | 30 | 43 | 46 |
| Operating income | 5.5 | (146) | (92) | (43) | (36) |
| Interest expense | 9.7 | 6 | 3 | 0.4 | – |
| Pre-tax income | (5.9) | (147) | (131) | (14) | (45) |
| Income tax | 3.6 | (10) | 0 | (0.1) | 0 |
| Net income | (9.5) | (136) | (131) | (14) | (45) |
| Diluted EPS | −C$0.07 | −C$0.79 | −C$0.51 | −C$0.18 | −C$0.48 |
| Diluted shares (millions) | 152 | 178 | 256 | 77 | 95 |
1 older year available with the 10-year history. Essential plan, from €8.25/month →
1.26 Grey zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
6/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Sep 30, 2025 · Data updated Dec 18, 2024